Myria Nikolaou

A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2− Primary Breast Cancer

J.F.R. Robertson, Abigail Evans, Stephan Henschen et al. · Clinical Cancer Research · 2020 · 48 citations · Full text

Medicine, Oncology, Pharmacology +17

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for <i>PIK3CA</i> -Dependent Breast Cancers

Kevin Hudson, Urs J. Hancox, Cath Trigwell et al. · Molecular Cancer Therapeutics · 2016 · 42 citations · Full text

Medicine, Oncology, Pharmacology +13

A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

Atish D. Choudhury, Celestia S. Higano, Johann S. de Bono et al. · Clinical Cancer Research · 2022 · 40 citations · Full text

Medicine, Oncology, Pharmacology +16

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer

Lillian M. Smyth, Gerald Batist, Funda Meric‐Bernstam et al. · npj Breast Cancer · 2021 · 36 citations · Full text

Medicine, Oncology, Pharmacology +17

Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC

Thomas G. Hayhow, Beth Williamson, Mandy Lawson et al. · Communications Biology · 2024 · 22 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16